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Abstract
Aims/hypothesis In type 1 diabetes, selective beta cell loss occurs within the inflamed milieu of insulitic islets. This milieu is
generated via the enhanced secretion of proinflammatory cytokines and by the loss of anti-inflammatory molecules such as IL-4
and IL-13. While the actions of proinflammatory cytokines have been well-studied in beta cells, the effects of their anti-
inflammatory counterparts have received relatively little attention and we have addressed this.
Methods Clonal beta cells, isolated human islets and pancreas sections from control individuals and those with type 1 diabetes
were employed. Gene expression was measured using targeted gene arrays and by quantitative RT-PCR. Protein expression was
monitored in cell extracts by western blotting and in tissue sections by immunocytochemistry. Target proteins were knocked
down selectively with interference RNA.
Results Cytoprotection achieved with IL-4 and IL-13 is mediated by the early activation of signal transducer and activator of
transcription 6 (STAT6) in beta cells, leading to the upregulation of anti-apoptotic proteins, including myeloid leukaemia-1
(MCL-1) and B cell lymphoma-extra large (BCLXL). We also report the induction of signal regulatory protein-α (SIRPα),
and find that knockdown of SIRPα is associated with reduced beta cell viability. These anti-apoptotic proteins and their attendant
cytoprotective effects are lost following siRNA-mediated knockdown of STAT6 in beta cells. Importantly, analysis of human
pancreas sections revealed that STAT6 is markedly depleted in the beta cells of individuals with type 1 diabetes, implying the loss
of cytoprotective responses.
Conclusions/interpretation Selective loss of STAT6may contribute to beta cell demise during the progression of type 1 diabetes.
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Abbreviations
BCLXL B cell lymphoma-extra large
EADB Exeter Archival Diabetes Biobank
FFPE Formalin-fixed paraffin embedded
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
HLAI HLA class I
ICI Insulin-containing islets
JAK Janus kinase
MCL-1 Myeloid cell leukaemia-1c
MFI Mean fluorescence intensity
nPOD Network for Pancreatic OrganDonorswithDiabetes
PI Propidium iodide
PI-3 K Phosphatidylinositol 3-kinase
siRNA Small interference RNA
SIRPα Signal regulatory protein-α
STAT6 Signal transducer and activator of transcription 6
Introduction
Type 1 diabetes arises following the selective destruction of
pancreatic beta cells by immune cells that infiltrate the islets
of Langerhans during disease development. In humans, these
infiltrates contain various different immune cell subtypes but
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are dominated by autoreactive CD8+ T cells [1–3], considered
to be the principal mediators of beta cell demise [4]. Loss of
beta cells occurs via a combination of direct cell-mediated
toxicity and the release of soluble factors (such as proinflam-
matory cytokines, granzymes and perforin) which promote
apoptosis [5–9]. However, the situation is complex since bal-
anced against these pro-apoptotic mechanisms favouring beta
cell loss are factors which act to sustain viability, including anti-
inflammatory cytokines such as IL-13 and IL-4. In common
with their proinflammatory counterparts, these may be secreted
from specific immune cell subsets [10–14] and might also orig-
inate from the islet cells. Irrespective of their precise source, the
final outcome of any inflammatory episode for beta cell viabi-
lity will be determined by the competing effects of these va-
rious antagonistic influences operating within the islet milieu.
The actions of proinflammatory cytokines have been well-
studied in beta cells [9, 12, 15–18] but, in contrast, the
counter-balancing effects of anti-inflammatory molecules
have received much less attention. Nevertheless, it is known
that exogenous administration of IL-13 or IL-4 reduces the
incidence and delays the onset of diabetes in the NOD mouse
model of type 1 diabetes [10, 19] and that IL-4 and IL-13 each
exert direct pro-survival effects in human pancreatic islet cells
[20–22]. Thus, it is likely that the availability of such mole-
cules within islets may influence the survival of beta cells in
the face of ongoing autoimmunity.
IL-4 and IL-13 share approximately 30% sequence ho-
mology [23] and both interact with cell surface receptors
containing the ‘IL-4RA’ subunit. In the case of IL-4, this
subunit is complexed with the common γ-chain to form the
functional receptor, whereas in the IL-13 receptor, IL-4RA
interacts with IL-13Rα1 [24]. All of these components are
expressed in human islets and on clonal beta cell lines [25,
26]. Upon binding of their cognate cytokines, each recep-
tor promotes the auto-phosphorylation of associated Janus
kinases (JAKs), leading to a cascade of events culminating
in the recruitment and phosphorylation of the transcription
factor, signal transducer and activator of transcription 6
(STAT6). In response, STAT6 monomers dimerise and
translocate to the nucleus where they bind to consensus
sequences in genomic DNA to promote the transcription
of target genes [27]. Previous studies have confirmed that
IL-13 treatment induces a robust and early phosphorylation
of STAT6 in the beta cell, in a JAK-dependent manner,
demonstrating that this pathway is operational in these
cells [20].
Despite this evidence, the mechanisms involved in promo-
ting beta cell viability in response to STAT6 activation are
unclear and it is not known whether this pathway is altered
during the autoimmune attack associated with type 1 diabetes.
Therefore, to address these issues, we have disrupted STAT6
signalling specifically in clonal beta cells and studied its
effects on the actions of IL-4 and IL-13.
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Methods
Imaging studies Human formalin-fixed paraffin-embedded
(FFPE) pancreas samples were obtained from the Exeter
Archival Diabetes Biobank (http://foulis.vub.ac.be/), an
archival collection of post-mortem pancreas samples [28].
These consisted of six samples taken from individuals with
recent-onset type 1 diabetes plus six control samples from
individuals of similar age and sex (ESM Table 1). All samples
were studied with full ethical approval (15/W/0258).
Where a single antigen was examined, sections were stu-
died using immunoperoxidase staining. In these experiments,
samples were dewaxed, rehydrated and heated in a citrate
antigen retrieval buffer (pH 7.4) for 20min using a microwave
(800W). Sections were blocked in 5% (vol./vol.) normal goat
serum and then probed with primary and relevant secondary
antibodies (ESM Table 2). Haematoxylin was used as a coun-
terstain prior to mounting of the section in distyrene–xylene-
based mountant. Alternatively, where two or more antigens
were examined, sections were sequentially stained with pri-
mary antibodies and species-appropriate fluorescently
labelled secondary antisera prior to mounting. Antisera were
validated either using relevant control tissues or were used in
accordance with manufacturers’ instructions.
Images were captured using an AF6000 fluorescent micro-
scope (Leica Microsystems, Milton Keynes, UK). For quanti-
fication studies, randomly selected insulin-containing islets
from individuals with and without diabetes were imaged using
identical microscope and camera settings. Regions of interest
were drawn around the islet periphery and the mean fluores-
cence intensity (MFI) of each antigen was assessed using
Image J version 1.50b (https://imagej.nih.gov/ij/) with Java
1.8.0_77 https://www.oracle.com/technetwork/java/javase/
8u77-relnotes-2944725.html). Alternatively, the MFI of
STAT6 immunostaining was calculated only in insulin-
positive regions using a custom MATLAB script (version
R2015b) (www.mathworks.com/products/new_products/
release2015b.html), VIOLA, developed in house (University
of Exeter). The VIOLA script identifies insulin-positive re-
gions within each image by thresholding against insulin-
negative regions. It then reports the MFI of a second antigen
(in this case STAT6) only in areas where the two are co-
localised.
Cell culture and treatmentsCultured INS-1E cells (a gift from
C. Wollheim, University of Geneva, Switzerland) were used
to perform most in vitro experiments. Cell culture was
achieved in RPMI-1640 at 11 mmol/l glucose (Lonza, Basel,
Switzerland) supplemented with 10% FBS, 2 mmol/l L-gluta-
mine, 100 U/ml penicillin, 100 μg/ml streptomycin and
50 mmol/l 2-mercaptoethanol (all from ThermoFisher,
Boston, MA, USA) and treatments were performed at 2 ×
105 cell/ml seeding density [29]. Cells were treated with
20 ng/ml of each cytokine (IL-4, IL-13, IL-1β, TNF-α,
IFN-γ and IL-6; all from R&D systems, Abingdon, UK),
250 μmol/l palmitic acid complexed to 1% bovine serum
albumin or after serum withdrawal for the desired duration.
These concentrations were chosen since they had been shown
to be effective in our previous studies [20, 30]. Human
EndoC-βH1 beta cells were sourced and cultured as described
in [31]. Cells were routinely tested for mycoplasma contami-
nation and were negative.
Knockdown of STAT6 and SIRPα Knockdown of target tran-
scripts was achieved using small interference RNAs (siRNAs)
for rat Stat6 and Sirpα (also known as Sirpa) (ThermoFisher).
Cells were transfected with target or scrambled siRNA.
Scrambled siRNA was generated randomly from the Stat6
sequence (GAAUUAAUCGUCGUCUU), and tested against
the NCBI database to confirm the lack of off-target effects.
Commercial siRNA sequences are proprietary. Optimem
(ThermoFisher) and lipofectamine RNAi Max (Invitrogen,
Boston, MA, USA) were used as transfection reagents and
successful knockdown was confirmed by western blotting
and/or quantitative reverse transcription PCR (qRT-PCR).
Overexpression of SIRPα
SIRPα was overexpressed in INS-1E cells using a pCMV6
vector containing the SIRPΑ coding sequence (Origene,
Rockville, MD, USA). Transfection of this construct or an
empty vector was performed using Lipofectamine LTX
reagent (Invitrogen) 24 h prior to each experiment.
Transfection was confirmed by western blotting and/or qRT-
PCR.
Western blottingCellular proteins were extracted and used for
western blotting as previously described [20]. Primary anti-
bodies (ESM Table 2) were added at 4°C in blocking solution
unless stated otherwise. After overnight incubation, mem-
branes were washed for 15 min in tris-buffered saline–
Tween (TBST) and probed with appropriate alkaline
phosphatase-conjugated secondary antibodies (Merck,
Darmstadt, Germany) for 1 h at room temperature. Bands
were detected with CDP-star chemiluminescent substrate
(Merck) or by Licor Odyssey detection system (Licor,
Cambridge, UK) when fluorescent secondary antibodies were
used. Densitometric analysis was performed using Image
Studio version 5.2 (https://www.licor.com/bio/products/
software/image_studio/) after normalising for expression of
β-actin or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH).
qRT-PCRRNAwas extracted from cells using an RNeasyMini
kit (Qiagen, Hilden, Germany) and its quantity and quality
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were estimated by NanoDrop measurement (ThermoFisher).
RNA (500 ng) was used for cDNA synthesis (Qiagen) and
gene expression was monitored by qRT-PCR with SYBR
Green master mix using commercially available RT2 Profiler
PCR Array and primers for genes of interest (Qiagen).
Amplicons were generated on the QuantStudio Flex 12K
(Applied Biosystems, Boston, MA, USA) and gene expres-
sion was calculated using the comparative threshold cycle
method (2−ΔΔCt ) after normalising with transcripts encoding
Hprt1 and Yy1 [32].
Cell viability measurements Viability was estimated using
either Trypan Blue (0.4% wt/vol. in PBS) or propidium iodide
(PI) (Merck) as previously described [26]. Routinely, each
experimental condition was replicated six times and indivi-
dual experiments were repeated on at least three separate
occasions.
Cell cycle analysis by flow cytometry A single time point cell
cycle analysis was performed by PI staining as described [33].
StatisticsAll statistical analyses were performed on Graphpad
Prism version 7.0 (https://www.graphpad.com/scientific-
software/prism/) and data are presented as mean values ±
SEM. Unpaired Student’s t test or ANOVA (with post hoc
Tukey’s test) were used to assess statistical significance
between mean values. Data were considered statistically
significant when p < 0.05.
Results
IL-13 and IL-4 each induce STAT6 phosphorylation and
cytoprotection in cultured beta cells The cytoprotective ac-
tions of IL-13 were investigated in rodent INS-1E and human
EndoC-βH1 cells. As expected, withdrawal of serum or treat-
ment of INS-1E cells with a proinflammatory cytokine cock-
tail caused a dramatic loss of viability, which was attenuated
by IL-13 (Fig. 1b–c). IL-4 also protected beta cells against
serum withdrawal (serum withdrawal 53.5 ± 1.5% cell death;
serum withdrawal + IL-4 44.4 ± 1.1%; p < 0.01). Importantly,
an equivalent cytoprotective response to IL-13 was also ob-
served in EndoC-βH1 cells treated with proinflammatory cy-
tokines (Fig. 1d), confirming that the response is not restricted
only to rodent cells. IL-13 treatment of INS-1E cells led to
increased tyrosine phosphorylation of STAT6 (Fig. 1a) within
15 min and, as seen previously [20], three separate immuno-
reactive pSTAT6 bands could be detected by western blotting,
all of which were enhanced in response to IL-13.
Silencing of STAT6 abrogates the cytoprotective effect of IL-
13 To understand the importance of STAT6 in mediating the
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Fig. 1 STAT6 is phosphorylated in response to IL-13 and protects beta
cells from the effects of serumwithdrawal or addition of proinflammatory
cytokines. (a) INS-1E cells were treated with IL-13 (20 ng/ml) for 45min.
The cells were lysed and protein extracted for western blotting to detect p-
STAT6, total STAT6 and β-actin. (b–d) INS-1E cells (b, c) or EndoC-
βH1 cells (d) were treated with IL-13 (20 ng/ml) for either 96 h in the
absence of serum (b) or for 48 h in the presence of a proinflammatory
cytokine cocktail (20 ng/ml of IL-1β, TNFα, IFNγ and IL-6) (c, d). Cell
viability was determined either by Trypan Blue (b, c) or PI staining (d).
All data represent mean values from three independent experiments ±
SEM. **p<0.01 and ***p<0.001 as indicated
90 Diabetologia (2019) 62:87–98
cytoprotective response to IL-13 in beta cells, siRNAmolecules
targeting Stat6 selectively were employed. Transfection of Stat6
siRNA into INS-1E cells caused an approximately 75% reduc-
tion in STAT6 protein levels relative to the scrambled siRNA-
treated control cells, within 48 h (Fig. 2a). STAT6 knockdown
was stable for at least 4 days (Fig. 2b) but returned to pre-
treatment levels within 6 days of transfection (not shown).
To examine the effect of depletion of STAT6 on the ability of
IL-13 to promote cytoprotection, siRNA directed against Stat6
was transfected into cells for a period of 24 h prior to treatment
with IL-13. The cells were then exposed either to a period of
serum withdrawal or were treated with a cocktail of proinflam-
matory cytokines or 250 μmol/l palmitate. As expected, IL-13
improved the viability of cells incubated under each of these
conditions (Fig. 2c, e). By contrast, when STAT6 was knocked
down prior to IL-13 treatment, the cytoprotective responses
were abrogated. The protective action of IL-4 was similarly
sensitive to STAT6 knockdown (Fig. 2d). Interestingly, howev-
er, knockdown of STAT6 did not itself lead to any loss of beta
cell viability in the absence of a specific cytotoxic stimulus.
Anti-apoptotic and anti-inflammatory genes are upregulated
following IL-13 treatment of INS-1 cells in a STAT6-dependent
manner Given that the cytoprotective response to IL-13, me-
diated by STAT6, was most evident following a period of pre-
treatment in INS-1E cells, we next examined whether it was
accompanied by changes in gene expression. To our know-
ledge, the transcriptional response to STAT6 activation has not
been characterised extensively in beta cells. Therefore, RNA
was extracted from INS-1E cells treated with IL-13 for 48 h
and cDNAwas synthesised for analysis using a targeted PCR
array. A range of genes were upregulated robustly under these
conditions, with the largest increases observed in the levels of
Sirpα, Mcl1, Bcl2l1, Epor, Smad1, Ptpn1, Socs1 and Sh2b1
(Fig. 3a). qRT-PCR analysis confirmed that Sirpα and Socs1
were significantly upregulated by IL-13 (Fig. 3b, c) whereas
the increases in Bcl2l1 and Mcl1 did not achieve statistical
significance by this method (Fig. 3d,e). Importantly, however,
western blot analysis confirmed the upregulation of signal
regulatory protein α (SIRPα), myeloid cell leukaemia-1
(MCL1) and B cell lymphoma-extra large (BCLXL), the gene
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Fig. 2 Silencing of Stat6
abrogates the cytoprotective
effects of IL13. (a, b) INS-1E
cells were transfected with siRNA
targeting Stat6 (knockdown
[KD]) or with a scrambled control
siRNA (SC), and incubated for up
to 96 h. Cell lysates were
extracted and western blotting
performed. Membranes were
probed with antisera recognising
STAT6 and β-actin. Expression
of STAT6 was quantified after
48 h knockdown by densitometric
analysis, with data expressed
relative to β-actin (n=3). (c–e)
STAT6 expression was depleted
with siRNA for 24 h prior to
addition of IL-13 (20 ng/ml) (c, e)
or IL-4 (20 ng/ml) (d). Cells were
incubated in the absence of serum
for 96 h (c, d) or in the presence of
a proinflammatory cytokine
cocktail (20 ng/ml of IL-1β,
TNFα, IFNγ and IL-6) or 250
μmol/l palmitate, as shown, for
48 h (e). Cells were harvested and
viability was assessed by Trypan
Blue staining. Data represent
mean values from three
independent experiments ± SEM.
*p<0.05, **p<0.01 and
***p<0.001 as indicated
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product of Bcl2l1, following exposure of INS-1E cells to
IL-13 (Fig. 4a, ESM Fig. 1). Exposure of cells to IL-4
increased Socs1, Sirpα, Bcl2l1, and Epor mRNA levels
(Fig. 3b–d, f) and, as in the case of IL-13, this was con-
firmed at the protein level in cell extracts (Fig. 4a, c, ESM
Fig. 1). Neither IL-13 nor IL-4 altered Ifngr1 expression
as judged by qRT-PCR analysis, despite the large increase
in expression observed in the PCR array (Fig. 3g).
Knockdown of STAT6 abrogated the stimulatory effects
of IL-13 and IL-4 on Sirpα, Socs1and Bcl2l1 mRNA and
their corresponding gene products (Figs 3b–d, f, g and
4c). Equivalent IL-13-induced changes in SIRPα were
observed in human EndoC-βH1cells (Fig. 4b). MCL-1
protein expression was elevated in response to IL-13 in
human EndoC-βH1cells, although the effects on BCLXL
were less marked in these cells (Fig. 4b).
SIRPα is a novel regulator of beta cell viability Among the
gene products found to be upregulated by IL-13 and IL-4,
SIRPα was the most unexpected. This protein is normally
expressed at high levels on myeloid cells [34]. It has been
studied only rarely in pancreatic beta cells, although we have
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Fig. 3 IL-13 stimulation of INS-1
cells induces the upregulation of
apoptotic and anti-inflammatory
genes in a STAT6-dependent
manner. (a) RNA extracted from
INS-1 cells treated with or
without IL-13 (20 ng/ml) for 48 h
was used to generate cDNA. The
samples were analysed using a
JAK/STAT RT2 Profiler PCR
Array to identify genes for which
expression was altered by IL-13.
(b–h) Specific primers were
generated for qRT-PCR analysis
of a selection of genes
upregulated in the array: Socs1
(b), Sirpα (c), Bcl2l1 (d), Mcl1
(e), Epor (f), Ifngr1 (g) and B2m
(h). qRT-PCR was performed on
cDNA generated from
unmodified INS-1 cells, from
cells in which STAT6 was
selectively knocked down or from
cells treated with IL-4 or IL-13 for
48 h. Gene expression (calculated
as fold change) was measured
after normalising the data to Yy1
and Hprt1 genes. In (a), data
represent fold change vs control
(without IL-13); (b–h), data
represent fold change vs relevant
control treatment and are mean
values from three independent
experiments ± SEM. *p<0.05,
**p<0.01 and ***p<0.001
relative to control; †††p<0.001
relative to IL-4; ‡p<0.05, ‡‡
p<0.01, ‡‡‡p<0.001 relative to IL-
13. Con, control; KD, STAT6
knockdown
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noted a report implicating SIRPα (also known as Src homolo-
gy 2 [SH2] domain-containing protein tyrosine phosphatase
substrate 1 [SHPS-1]) in the control of insulin secretion [35].
We therefore used primary human islets and were able to verify
that treatment with IL-13 resulted in a marked increase in
SIRPα expression (Fig. 5a). To study the effects of SIRPα in
more detail, we then used siRNA constructs to silence the
protein in INS-1E cells. SIRPα expression was robustly
knocked down over a period of at least 4 days by the targeted
siRNA treatment, as confirmed by qRT-PCR (Fig. 5b) and
western blot analysis (Fig. 5c). Importantly, knockdown of
SIRPα did not alter the level of STAT6 in INS-1E cells (Fig.
5c). Surprisingly, however, under basal conditions, knockdown
of SIRPα significantly enhanced beta cell death compared with
cells treated with scrambled control siRNA (Fig. 5d). Analysis
of the sub-G1 peak (corresponding to fragmented DNA) by
flow cytometry confirmed the increase in cell death associated
with depletion of SIRPα (Fig. 5e). Moreover, cell death in-
duced by the withdrawal of serum from cells was exacerbated
by the loss of SIRPα (Fig. 5d). It was then assessed whether
increasing the expression of SIRPα in beta cells could induce
the opposite effect, and promote cell viability. As expected, in
these experiments, SIRPα over-expression significantly im-
proved the viability of INS-1E cells cultured in the absence
of serum (Fig. 5f). Taken together, these data implicate
SIRPα as a novel regulator of beta cell viability whose levels
are controlled in a STAT6-dependent manner.
STAT6 is expressed in human pancreatic beta cells and is
diminished in the islets of individuals with type 1 diabetes
Immunohistochemical staining of STAT6 in human pan-
creas tissue from non-diabetic donors revealed a robust
expression of the protein in a subset of cells in pancreatic
islets, with much lower levels observed in the surrounding
exocrine tissue (Fig. 6a). Co-immunofluorescence staining
revealed that STAT6 is strongly co-localised with insulin,
but not with glucagon, suggesting its preferential expres-
sion in beta cells (ESM Fig. 2).
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Fig. 4 SIRPα, BCLXL and
MCL1 are upregulated by IL-13
via STAT6. INS-1E cells (a, c), or
EndoC-βH1 cells (b) were
stimulated with IL-13 (20 ng/ml)
(a–c) and/or IL-4 (20 ng/ml) (a, c)
for 48 h, and cell lysates collected.
In some experiments, IL-13 or IL-
4 was employed after STAT6
knockdown (KD). Western
blotting analysis was performed
and membranes probed using
antisera against SIRPα, BCLXL
and MCL1. GAPDH was used as
a loading control. These data are
representative of three
independent experiments
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To determine whether STAT6 expression is altered in dia-
betes, a series of six pancreas samples from individuals with
recent-onset type 1 diabetes and from six healthy control do-
nors with similar age and sex profiles were used. As expected,
STAT6 was expressed robustly within the islets of control
individuals but it was noticeably reduced in the insulin-
containing islets (ICIs) of people with type 1 diabetes
(Fig. 6a–c). To quantify these changes in expression, four or
five ICIs from each individual were imaged using identical
microscope and camera settings. Measurements of the MFI
of the anti-STAT6 immunolabelling confirmed the downreg-
ulation of STAT6 in ICIs in type 1 diabetes (Fig. 6c, d). As
previously reported, HLA class I (HLAI) expression was sig-
nificantly elevated in ICIs with depleted STAT6 expression
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Fig. 5 SIRPα is expressed in human islets and is a novel regulator of beta
cell viability. (a) Western blot analysis was performed on protein lysates
extracted from isolated human islets incubated under control conditions or
with IL-13 (20 ng/ml) and the membranes probed with an antiserum
against SIRPα. GAPDH was used as a loading control. (b, c) Sirpα ex-
pression was silenced in INS-1E cells over a 96 h period using siRNA.
Knockdown of SIRPα (blue bars) was confirmed by (b) qRT-PCR mea-
surement of Sirpa mRNA with data normalised using Yy1 and Hprt1 as
housekeeping genes or (c) was assessed by western blotting, with mem-
branes probed using antibodies raised against SIRPα, STAT6, STAT3 and
GAPDH. (d, f) To examine the impact of SIRPα on beta cell viability,
SIRPαwas either (d) knocked down in INS-1E cells using specific siRNA
molecules or (f) overexpressed using a SIRPA containing vector. In both
experiments, transfection was performed 24 h prior to culture for a further
96 h under serum-deprived conditions. Cell viability was assessed by flow
cytometry after this time. (e) Alternatively, cell cycle analysis was per-
formed following SIRPα knockdown (blue bars). Here, cells were fixed
in 95% ethanol prior to PI staining and analysis by flow cytometry.
Indicated values were normalised after subtracting sub-G0/G1 cells. Data
represent mean values from three independent experiments ± SEM.
Representative blots are shown. ***p<0.001 as indicated. Con, control;
KD, SIRPα knockdown; SD, serum-deprived condition
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from subjects with type 1 diabetes (Fig. 6e). Since the EADB
cohort is primarily an archival collection of post-mortem sam-
ples, we verified these data with samples from the Network for
Pancreatic Organ Donors with Diabetes (nPOD) collection of
organ donor pancreases. Immunofluorescence analysis
revealed a similar pattern, with STAT6 robustly expressed in
ICIs from healthy individuals but diminished in the islets of
individuals with type 1 diabetes (ESM Fig. 3).
To investigate this phenomenon further, we considered the
possibility that changes in the islet milieu associated with the
development of diabetes might be involved in promoting the
loss of STAT6. Accordingly, we used INS-1E cells which, like
human islets, express high levels of STAT6 when cultured
under control conditions. However, western blot analysis
revealed that when these cells were treated with proinflamma-
tory cytokines (IL1β, IFNγ, TNFα and IL-6) for 48 h or were
exposed to either 250 μmol/l palmitate or conditions of serum
withdrawal, STAT6 was significantly depleted (Fig. 7a, b).
Interestingly, pre-treatment of the cells with IL-13 for 48 h
led to an increase in STAT6 expression relative to control
conditions (Fig. 7c), suggesting a feed-forward upregulation
of STAT6 in cells exposed to the anti-inflammatory cytokine.
Moreover, addition of IL-13 resulted in partial preservation of
STAT6 expression in cells treated with the proinflammatory
cytokine cocktail (Fig. 7c).
Discussion
We show that activation of STAT6 plays an important role in
maintaining the viability of pancreatic beta cells by promoting
the transcription of a variety of anti-apoptotic target genes.
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Moreover, we reveal that the expression of STAT6 is signifi-
cantly diminished in the beta cells of individuals with type 1
diabetes and propose that this is likely to enhance their sus-
ceptibility to the actions of proinflammatory cytokines during
disease progression. We further show that depletion of STAT6
occurs in vitro when islet cells are exposed to proinflammato-
ry cytokines or the saturated fatty acid palmitate (Fig. 7), sug-
gesting that its loss may be consequent to the development of
beta cell stress. Hence, our studies place STAT6 as a central
component of the regulatory network controlling beta cell
viability.
These conclusions arise from an analysis of the signalling
pathways activated by two anti-inflammatory cytokines, IL-4
and IL-13, which culminate in STAT6 activation in beta cells.
We confirm that both cytokines can protect beta cells against
the cytotoxic effects of serum deprivation (used as a surrogate
for growth factor withdrawal) and the presence of either pro-
inflammatory cytokines [20–22, 25] or palmitate (Fig. 2),
thereby suggesting that they are likely to be important in the
context of the inflammatory milieu associated with diabetes.
Although their precise origins during islet inflammation are
uncertain, IL-13 and/or IL-4 may be released by specific sub-
sets of immune cells recruited to islets during the process of
insulitis. Additionally, the islet cells themselves are a potential
source since IL-13 gene expression has been detected in human
islets [36]. Irrespective of the endogenous sources, however,
the cytoprotective effects achieved upon exogenous addition of
IL-13 or IL-4 to beta cells were prevented by knockdown of
STAT6, consistent with the view that a functional STAT6 path-
way is required to mediate protection.
This conclusion differs from that reached recently by Rutti
et al [21], who argued that the phosphatidylinositol 3-kinase
(PI-3K)–Akt pathway may be of specific importance in
mediating the cytoprotective effects of IL-13 in primary hu-
man beta cells. In considering these differences, we accept that
it is entirely possible that multiple pathways are involved in
the response but also note that the PI-3K inhibitor,
wortmannin, failed to influence the cytoprotective response
to IL-13 in rodent beta cells [20].
When investigating the time course over which IL-13
exerts its effects in beta cells, it was observed that tyrosine
phosphorylation of STAT6 occurs as an early event but that
full cytoprotection required a much longer period of incuba-
tion with IL-13. This is consistent with the accepted model in
which phosphorylation of STAT6 is followed by its transloca-
tion to the nucleus and the subsequent transcription of specific
target genes [27]. Accordingly, we sought to identify potential
candidate genes and noted that, among a range of target mole-
cules, two well-known anti-apoptotic genes, MCL1 and
BCL2L1, were markedly increased under conditions of
STAT6 activation. This was confirmed at the protein level,
thereby placing these gene products as being of potential im-
portance inmediating the cytoprotective response to cytokines
acting via STAT6. Both proteins are well described as anti-
apoptotic molecules in the context of the beta cell [37–40] and
the present data demonstrating a loss of STAT6 from beta cells
in type 1 diabetes implies that anti-apoptotic responses could
be downregulated under these conditions. Consistent with
this, we have shown previously thatMCL-1 levels are reduced
in certain beta cells in the islets of people with type 1 diabetes
[41] and it is worth noting that MCL-1 was also downregula-
ted following the treatment of INS-1E cells with proinflam-
matory cytokines [42]. The current results imply that these
effects might be contingent on STAT6 depletion.
Despite the alterations in MCL1 and BCL2L1, the gene
which was most robustly increased in beta cells or human
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Fig. 7 STAT6 levels are diminished in cultured INS-1E cells exposed to
cytotoxic stimuli and this response is attenuated by IL-13. (a, b) INS-1E
cells were cultured in the presence or absence of a proinflammatory cy-
tokine cocktail (20 ng/ml of IL-1β, TNFα, IFNγ and IL-6) or 250 μmol/l
palmitate for 48 h (a) or in serum-deprived (SD) media for 96 h (b). (c)
Alternatively, cells were cultured under these same conditions but in the
presence of IL-13. Cell lysates were collected and western blotting per-
formed using antiserum recognising STAT6 (or GAPDH as a loading
control). Data are representative of three independent experiments. Con,
control
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islets treated with IL-13 was SIRPα. This gene encodes a
protein, SIRPα (also known as SHPS-1), which is widely
understood to function as a regulator of immune responses
[43] but which has received relatively little attention in beta
cells. An earlier report has implicated SIRPα in the control of
insulin secretion [35] but we are not aware of any previous
evidence implicating SIRPα in the control of beta cell viabil-
ity or of any strong evidence for SIRPα being a target gene for
STAT6. Thus, it was important to consider the functional role
of SIRPα more fully and, accordingly, interference RNA ap-
proaches were employed to deplete the expression of the mol-
ecule in beta cells. These studies revealed that knockdown of
SIRPα led to a loss of the cytoprotective actions of IL-4 and
IL-13 and that depletion of SIRPα also caused a net reduction
in beta cell viability under non-stimulating conditions. On this
basis, we propose that SIRPα may function as a previously
unrecognised regulator of beta cell viability and that increases
in SIRPα, mediated by activation of STAT6, represent one
important component of the downstream effector pathway
by which IL-13 and/or IL-4 promote beta cell cytoprotection.
The present work does not reveal the molecular pathways by
which SIRPα achieves these effects but we note that beta cells
also express abundant levels of its cognate binding partner,
CD47 (K. A. Leslie, M. A. Russell and N. G. Morgan [prin-
cipal investigator]; unpublished observations), implying that a
functional signalling complex might be formed in these cells.
Interestingly, despite the loss of viability seen in the
absence of a cytotoxic stimulus when SIRPα was knocked
down, a similar effect was not observed upon depletion of
STAT6. Rather, under these conditions, the basal viability of
the cells was unaffected. These results suggest that STAT6 is
unlikely to be involved in driving the constitutive expression
of SIRPα in beta cells but imply that it is required to mediate
the increase in expression seen upon exposure of cells to IL-13
or IL-4. Given that this then enhances the propensity of the
cells to resist the effects of cytotoxic insults, these results
suggest that decreases in STAT6 and SIRPα could contribute
to beta cell demise during the progression of type 1 diabetes in
susceptible individuals.
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